Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Current Assets for 10 consecutive years, with $253.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 122.22% to $253.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $253.0 million through Dec 2025, up 122.22% year-over-year, with the annual reading at $253.0 million for FY2025, 122.22% up from the prior year.
  • Current Assets for Q4 2025 was $253.0 million at Akebia Therapeutics, down from $258.3 million in the prior quarter.
  • The five-year high for Current Assets was $365.0 million in Q1 2021, with the low at $100.1 million in Q3 2024.
  • Average Current Assets over 5 years is $209.7 million, with a median of $219.2 million recorded in 2025.
  • The sharpest move saw Current Assets crashed 61.57% in 2023, then skyrocketed 158.03% in 2025.
  • Over 5 years, Current Assets stood at $271.1 million in 2021, then crashed by 31.7% to $185.2 million in 2022, then plummeted by 36.2% to $118.1 million in 2023, then decreased by 3.65% to $113.8 million in 2024, then surged by 122.22% to $253.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $253.0 million, $258.3 million, and $234.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.